Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) - Tabular View

Tracking Information
First Received Date ^ICMJE	July 19, 2002
Last Updated Date	October 12, 2009
Start Date ^ICMJE	July 2002
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00042016 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Official Title ^ICMJE	A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Chronic Phase Refractory to Imatinib Mesylate (STI 571)
Brief Summary	To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia chronic phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.
Detailed Description
Study Phase	Phase II
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Condition ^ICMJE	Chronic Myelogenous Leukemia
Intervention ^ICMJE	Drug: decitabine (5-aza-2'deoxycytidine)
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	40
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion: Histologically confirmed diagnosis of CML chronic phase Ph chromosome-positive Previous treatment with imatinib mesylate resulting in: i) Hematologic Resistance / Hematologic Refractory: Based on a physician's (documented) decision to discontinue imatinib mesylate treatment due to failure of continued benefit or no benefit to the patient, ii) Imatinib Mesylate Intolerance: any toxicity resulting in a physician's (documented) decision to discontinue imatinib mesylate treatment. Patients must have recovered from the side effects of previous CML therapy for chronic phase with the exception of hydroxyurea Age >/= 2 years Bilirubin </= 3 x the upper limit of normal (ULN), SGOT and SGPT </= 3 x ULN, except </= 5 x ULN in leukemic involvement of the liver, serum creatinine </= 2 x ULN WHO performance status 0-3 A negative serum hCG pregnancy test in patients of childbearing potential Able to give signed informed consent directly or through a parent or guardian for minors Exclusion: Leukemic involvement of the central nervous system Active malignancy other than CML or non-melanoma cancer of the skin Previous treatment for CML with another investigational agent within 28 days of study entry At study entry, patients who were treated with: imatinib mesylate within the past 48 hours; interferon-alpha within the past 48 hours; homoharringtonine within the past 14 days; low-dose cytosine arabinoside within 7 days, moderate dose within 14 days, or high dose within 28 days; etoposide, anthracyclines, or mitoxantrone within 21 days; busulfan within the past six weeks Patients who had received hematopoietic stem cell transplantation within 6 weeks of Day 1 decitabine therapy Patients with Grade 3/4 cardiac disease or any other serious concurrent medical condition. Patients who are pregnant or nursing. All patients of childbearing potential must practice effective methods of contraception while on study. Patients with mental illness or other condition precluding their ability to give informed consent or to comply with study requirements Patients with systemic, uncontrolled infections
Gender	Both
Ages	2 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States, Canada

Administrative Information
NCT ID ^ICMJE	NCT00042016
Responsible Party
Study ID Numbers ^ICMJE	DAC-014, DACO-014
Study Sponsor ^ICMJE	SuperGen
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	SuperGen
Verification Date	June 2005
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP